
A bortezomib (Velcade)-based regimen significantly improved progression free survival (PFS) and consistently improved secondary efficacy end points in previously untreated mantle cell lymphoma (MCL) patients compared to standard therapy, according to data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.



